Our results indicate that higher baseline serum levels of Ang-2 are associated with poor prognosis in stage IIIβ NSCLC, while high baseline Ang-2 serum concentration is an independent factor of poor prognosis in stage IIIβ NSCLC (hazard ratio = 2.97, 95% CI: 1.05–8.40, p = 0.04, Table 3) [14,16,26,27]. Here, ANGPT2 is linked to non-small cell lung carcinoma.